Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK-positive Anaplastic Thyroid Cancer
NCT02289144Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in anaplastic thyroid cancer (ATC), undifferentiated thyroid cancer (ATC), sponsored by UT Southwestern Medical Center. Planned start Jun 2015; status: withdrawn.
02
Drugs
ceritinib
03
Conditions
anaplastic thyroid cancer (ATC)undifferentiated thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT02289144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289144.